Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20901942 | 0.81 | LMNA (0.42) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL50543 | 0.80 | LMNA (0.46) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL212457 | 0.80 | LMNA (0.46) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL304175 | 0.80 | LMNA (0.46) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL4616133 | 0.80 | KMT2A (0.49) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL4200114 | 0.80 | TSHR (0.46) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL13196349 | 0.78 | LMNA (0.49) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4575259 | 0.78 | LMNA (0.45) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| Hydrochloric Acid SCHEMBL27398725 | 0.78 | LMNA (0.45) | LMNAKMT2AMEN1TSHRL3MBTL1 | |
| SCHEMBL4070446 | 0.77 | LMNA (0.55) | LMNAKMT2AMEN1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059010-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10329304-B2 | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase | VANDERBILT UNIVERSITY (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2018-08-09 | — | — | US | disclosed |
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2018-08-09 | — | — | US | disclosed |
| US-9938275-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938275-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180057509-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180057509-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2018-03-01 | — | — | US | disclosed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| EP-1187811-B1 | INHIBITORS OF METALLOPROTEINASES | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | EP | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004004646-A2 | O-DERIVATIZED NOCATHIACIN DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | LMNA 3602/4885KMT2A 4055/4885MEN1 2531/4885 |
| US-10329304-B2 | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase | PDE4A, PDE4B, PDE7A | LMNA 3846/4885KMT2A 3118/4885MEN1 1826/4885 |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | IL2, IFNG, IRF3 | LMNA 3758/4885KMT2A 2789/4885MEN1 3720/4885 |
| US-20180057509-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, IFNG, TSLP | LMNA 4594/4885KMT2A 3303/4885MEN1 3024/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | LMNA 4386/4885KMT2A 1449/4885MEN1 3032/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | LMNA 2744/4885KMT2A 2592/4885MEN1 2927/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | LMNA 2744/4885KMT2A 2592/4885MEN1 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.